Cytogen Durchbruch geschafft ! - 500 Beiträge pro Seite
eröffnet am 22.06.00 19:59:37 von
neuester Beitrag 24.10.00 01:58:56 von
neuester Beitrag 24.10.00 01:58:56 von
Beiträge: 11
ID: 165.138
ID: 165.138
Aufrufe heute: 0
Gesamt: 762
Gesamt: 762
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 23:58 | 137 | |
| gestern 23:09 | 121 | |
| heute 00:01 | 102 | |
| gestern 23:31 | 79 | |
| vor 1 Stunde | 78 | |
| gestern 22:15 | 77 | |
| gestern 21:35 | 75 | |
| gestern 22:52 | 75 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.075,00 | +0,33 | 240 | |||
| 2. | 2. | 1,3800 | -1,43 | 98 | |||
| 3. | 3. | 0,1890 | -2,58 | 81 | |||
| 4. | 4. | 170,18 | +4,97 | 79 | |||
| 5. | 5. | 9,3325 | -3,69 | 75 | |||
| 6. | 6. | 7,0010 | +4,17 | 53 | |||
| 7. | 7. | 22,240 | -3,22 | 41 | |||
| 8. | 8. | 0,0160 | -24,17 | 38 |
Feedback
Riesenkursgewinn möglich ! Folgende Nachricht kam soeben:
Kursgewinn heute in USA: 18 % !!
Cytogen`s AxCell Biosciences Achieves Initial Proteomics Automation
ZURICH, Switzerland, June 19 /PRNewswire/ -- AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation (Nasdaq: CYTO - news), today announced that it had completed the first stage of its proteomics automation. Over the next month, AxCell plans to measure 135,000 protein interactions, with the expectation that the rate would increase to 200,000 per month by mid-summer. The Company also noted that it plans to complete the analysis of two to three protein domain families by the end of the year. The announcements were made this morning at the BioSpan Europe 2000 conference at the SWX Swiss Exchange here.
An important function of proteins is to facilitate cellular communication. Within the cytoplasm of the cell, proteins interact with one another in complex pathways that signal cells to secrete hormones, fire nerve signals, multiply, die, or destroy invading pathogens. Aberrations in the intracellular interactions of proteins with one other are at the heart of the molecular basis for many diseases, such as forms of cancer and diabetes.
``Pathways of protein-protein interactions control cellular function, and defects in these pathways can lead to disease,`` John D. Rodwell, Ph.D., AxCell`s acting President and Chief Technical Officer, explained to the gathering of European biotechnology investors. ``Proteins interact by `physically mating` with each other -- and thereby passing signals on to the next protein in the pathway. Of the approximately one million different proteins in humans, about 300,000 are believed to be involved in intracellular signaling pathways. Examining how all 300,000 signaling proteins might interact with one another would involve measuring some 90 billion interactions -- a Herculean labor. AxCell has found a way to simplify this task.``
``The structures by which proteins `mate` or interact are called domains and ligands,`` Dr. Rodwell continued. ``Domains are portions of proteins that can accept the smaller ligand within their structure and bind to it. Once you know which domains will interact with which ligands, you can develop rules of interaction for any proteins containing those interactive parts. Domains having similar structures have been classified into families, and given surnames such as WW, PDZ and SH3. We believe that elucidating how these domain families interact with sets of ligands is the shortcut to understanding how proteins interact within cells. Once you have identified protein signaling pathways involved in normal or diseased processes, it is possible to select novel targets for drug intervention within those pathways.``
``There are approximately 140 domain families in the human proteome, and we estimate 30 to 60 families are involved in signaling pathways,`` Dr. Rodwell stated. ``Despite their importance in understanding cellular function, no domain family has ever been fully characterized. So far, we have seen that the number of domain family members can vary from less than 100 to greater than 200. AxCell`s high throughput technology is beginning to prove itself, and we believe that we can completely chart human protein signaling interactions in two to four years. By completing the measurement of the first one million interactions -- including charting two to three domain families -- this year, we believe that our database will have reached a sufficient critical mass for marketing in early 2001. We believe that the WW domain will be the first family that we will fully characterize.``
AxCell Biosciences Corporation is conducting research and development in functional proteomics, the identification of protein interactions and signaling pathways within cells and their relationship to disease processes. Proteomics research efforts can be categorized as structural and functional. Structural proteomics, or protein expression, measures the number and types of proteins present in normal and diseased cells. This approach is useful in defining the structure of proteins in a cell. Some of these proteins may be targets for drug discovery. However, the role of the protein in the disease is still not defined. AxCell`s proteomics business is focused upon functional proteomics, the study of proteins` biological activities. Protein-protein interactions form the core of the Company`s Inter-functional Proteomic Database(TM) (IFP). AxCell plans to offer the IFP Database to the pharmaceutical industry as a tool to accelerate the drug discovery process. For additional information on AxCell Biosciences, visit http://www.axcellbio.com .
Cytogen Corporation is an established biopharmaceutical company in Princeton, NJ, with two principal lines of business, proteomics and oncology. The Company is extending its expertise in antibodies and molecular recognition to the development of new products and a proteomics-driven drug discovery platform. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA. The Company, with Progenics Pharmaceuticals, Inc., has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA technology. The Company`s cancer management franchise currently comprises three marketed FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit http://www.cytogen.com .
--> Kaufen !
Kursgewinn heute in USA: 18 % !!
Cytogen`s AxCell Biosciences Achieves Initial Proteomics Automation
ZURICH, Switzerland, June 19 /PRNewswire/ -- AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation (Nasdaq: CYTO - news), today announced that it had completed the first stage of its proteomics automation. Over the next month, AxCell plans to measure 135,000 protein interactions, with the expectation that the rate would increase to 200,000 per month by mid-summer. The Company also noted that it plans to complete the analysis of two to three protein domain families by the end of the year. The announcements were made this morning at the BioSpan Europe 2000 conference at the SWX Swiss Exchange here.
An important function of proteins is to facilitate cellular communication. Within the cytoplasm of the cell, proteins interact with one another in complex pathways that signal cells to secrete hormones, fire nerve signals, multiply, die, or destroy invading pathogens. Aberrations in the intracellular interactions of proteins with one other are at the heart of the molecular basis for many diseases, such as forms of cancer and diabetes.
``Pathways of protein-protein interactions control cellular function, and defects in these pathways can lead to disease,`` John D. Rodwell, Ph.D., AxCell`s acting President and Chief Technical Officer, explained to the gathering of European biotechnology investors. ``Proteins interact by `physically mating` with each other -- and thereby passing signals on to the next protein in the pathway. Of the approximately one million different proteins in humans, about 300,000 are believed to be involved in intracellular signaling pathways. Examining how all 300,000 signaling proteins might interact with one another would involve measuring some 90 billion interactions -- a Herculean labor. AxCell has found a way to simplify this task.``
``The structures by which proteins `mate` or interact are called domains and ligands,`` Dr. Rodwell continued. ``Domains are portions of proteins that can accept the smaller ligand within their structure and bind to it. Once you know which domains will interact with which ligands, you can develop rules of interaction for any proteins containing those interactive parts. Domains having similar structures have been classified into families, and given surnames such as WW, PDZ and SH3. We believe that elucidating how these domain families interact with sets of ligands is the shortcut to understanding how proteins interact within cells. Once you have identified protein signaling pathways involved in normal or diseased processes, it is possible to select novel targets for drug intervention within those pathways.``
``There are approximately 140 domain families in the human proteome, and we estimate 30 to 60 families are involved in signaling pathways,`` Dr. Rodwell stated. ``Despite their importance in understanding cellular function, no domain family has ever been fully characterized. So far, we have seen that the number of domain family members can vary from less than 100 to greater than 200. AxCell`s high throughput technology is beginning to prove itself, and we believe that we can completely chart human protein signaling interactions in two to four years. By completing the measurement of the first one million interactions -- including charting two to three domain families -- this year, we believe that our database will have reached a sufficient critical mass for marketing in early 2001. We believe that the WW domain will be the first family that we will fully characterize.``
AxCell Biosciences Corporation is conducting research and development in functional proteomics, the identification of protein interactions and signaling pathways within cells and their relationship to disease processes. Proteomics research efforts can be categorized as structural and functional. Structural proteomics, or protein expression, measures the number and types of proteins present in normal and diseased cells. This approach is useful in defining the structure of proteins in a cell. Some of these proteins may be targets for drug discovery. However, the role of the protein in the disease is still not defined. AxCell`s proteomics business is focused upon functional proteomics, the study of proteins` biological activities. Protein-protein interactions form the core of the Company`s Inter-functional Proteomic Database(TM) (IFP). AxCell plans to offer the IFP Database to the pharmaceutical industry as a tool to accelerate the drug discovery process. For additional information on AxCell Biosciences, visit http://www.axcellbio.com .
Cytogen Corporation is an established biopharmaceutical company in Princeton, NJ, with two principal lines of business, proteomics and oncology. The Company is extending its expertise in antibodies and molecular recognition to the development of new products and a proteomics-driven drug discovery platform. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA. The Company, with Progenics Pharmaceuticals, Inc., has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA technology. The Company`s cancer management franchise currently comprises three marketed FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit http://www.cytogen.com .
--> Kaufen !
Am besten Ihr kauft in Berlin WKN Nummer: 871813
Aktuell 10 $ in USA. Aktie steigt !
Hallo Broker07,
ich halte von Cytogen auch eine Menge, und bin mir auch sicher daß Sie heute noch weiterlaufen wird, aber an dieser Meldung lags mit Sicherheit nicht, denn die ist von Montag.
Das war mehr eine technische Erholung, deswegen geht das heute auch noch weiter.
Ich wünsche Dir Viel Glück mit CYTO
Ciao G_P
ich halte von Cytogen auch eine Menge, und bin mir auch sicher daß Sie heute noch weiterlaufen wird, aber an dieser Meldung lags mit Sicherheit nicht, denn die ist von Montag.
Das war mehr eine technische Erholung, deswegen geht das heute auch noch weiter.
Ich wünsche Dir Viel Glück mit CYTO
Ciao G_P
So langsam kommt Bewegung in die Aktie. Hier wieder sehr gute Nachrichten: In Amerika aktuell 10,12 $ !
Monday June 26, 7:00 am Eastern Time
Company Press Release
SOURCE: Cytogen Corporation
Cytogen Files for ProstaScint Regulatory Approval in Europe; Broader Geographical Marketing of Prostate Cancer Imaging Agent Sought
PRINCETON, N.J., June 26 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO - news) today announced that it has submitted a regulatory dossier to the European Agency for the Evaluation of Medicinal Products (EMEA) to obtain marketing approval of ProstaScint®, a radio- labeled monoclonal antibody for the imaging of metastatic prostate cancer. The ProstaScint application was submitted for regulatory review under a centralized procedure and, if successful, would give the Company the right to market the product throughout the 15 member countries in the European Union (EU). Such an approval would also allow Cytogen to seek expedited marketing approval in Central and Eastern European countries and other non-EU member countries which belong to the European Economic Area. The reviewing authority, the Committee for Proprietary Medicinal Products, has designated representatives from Sweden and the United Kingdom as the rapporteur and co-rapporteur, respectively.
``ProstaScint has been sold in the U.S. since 1997, and we are now seeking broader geographic markets for this important cancer imaging product,`` said H. Joseph Reiser, Ph.D., Cytogen`s Chief Executive Officer. ``The incidence of prostate cancer among European men is comparable to that in the U.S., where nearly 200,000 new cases will be diagnosed this year. Assuming a timely approval, we could launch sales of ProstaScint in Europe late next year. In addition, ProstaScint is under expedited review in Canada. We are also considering distribution agreements in other selected countries and regions such as South America.``
Cytogen Corporation is an established biopharmaceutical company in Princeton, NJ, with two principal lines of business, proteomics and oncology. The Company is extending its expertise in antibodies and molecular recognition to the development of new products and a proteomics-driven drug discovery platform. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies. The Company, with Progenics Pharmaceuticals, Inc., has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA technology. The Company`s cancer management franchise currently comprises three marketed FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com.
Information in this press release which is not historical is forward- looking and involves risks and uncertainties. Actual results may differ materially for various reasons including, the uncertainties associated with product development and acceptance of the Company`s products by the medical community, the risks and uncertainties associated with foreign regulatory approval processes and inherent dependence upon the actions of governmental agencies during the course of such processes, the ability of the Company to increase sales of its products, and other factors discussed in the Company`s Form 10-K Annual Report for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.
SOURCE: Cytogen Corporation
Monday June 26, 7:00 am Eastern Time
Company Press Release
SOURCE: Cytogen Corporation
Cytogen Files for ProstaScint Regulatory Approval in Europe; Broader Geographical Marketing of Prostate Cancer Imaging Agent Sought
PRINCETON, N.J., June 26 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO - news) today announced that it has submitted a regulatory dossier to the European Agency for the Evaluation of Medicinal Products (EMEA) to obtain marketing approval of ProstaScint®, a radio- labeled monoclonal antibody for the imaging of metastatic prostate cancer. The ProstaScint application was submitted for regulatory review under a centralized procedure and, if successful, would give the Company the right to market the product throughout the 15 member countries in the European Union (EU). Such an approval would also allow Cytogen to seek expedited marketing approval in Central and Eastern European countries and other non-EU member countries which belong to the European Economic Area. The reviewing authority, the Committee for Proprietary Medicinal Products, has designated representatives from Sweden and the United Kingdom as the rapporteur and co-rapporteur, respectively.
``ProstaScint has been sold in the U.S. since 1997, and we are now seeking broader geographic markets for this important cancer imaging product,`` said H. Joseph Reiser, Ph.D., Cytogen`s Chief Executive Officer. ``The incidence of prostate cancer among European men is comparable to that in the U.S., where nearly 200,000 new cases will be diagnosed this year. Assuming a timely approval, we could launch sales of ProstaScint in Europe late next year. In addition, ProstaScint is under expedited review in Canada. We are also considering distribution agreements in other selected countries and regions such as South America.``
Cytogen Corporation is an established biopharmaceutical company in Princeton, NJ, with two principal lines of business, proteomics and oncology. The Company is extending its expertise in antibodies and molecular recognition to the development of new products and a proteomics-driven drug discovery platform. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies. The Company, with Progenics Pharmaceuticals, Inc., has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA technology. The Company`s cancer management franchise currently comprises three marketed FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com.
Information in this press release which is not historical is forward- looking and involves risks and uncertainties. Actual results may differ materially for various reasons including, the uncertainties associated with product development and acceptance of the Company`s products by the medical community, the risks and uncertainties associated with foreign regulatory approval processes and inherent dependence upon the actions of governmental agencies during the course of such processes, the ability of the Company to increase sales of its products, and other factors discussed in the Company`s Form 10-K Annual Report for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.
SOURCE: Cytogen Corporation
Trading Spotlight
THERMOGENESIS CORP. Announces Issuance of Latest Patent for Device to Isolate Stem Cells From Blood
BusinessWire
Monday September 25 6:05am
RANCHO CORDOVA, Calif.--(BW HealthWire)--Sept. 25, 2000-- THERMOGENESIS CORP. (Nasdaq NM: KOOL) announced today that it has received notice from the U.S. Patent Office of the issuance of a patent describing a disposable bag set configured to isolate a stem cell rich fraction of blood into a fixed volume during centrifugation. THERMOGENESIS` patent portfolio includes 15 issued and eight pending U.S. patents.
Dr. James Godsey, President and COO of THERMOGENESIS CORP., noted that this improved bag set could be integrated into the BioArchive System of devices and disposals for processing hematopoietic stem cells from placental/umbilical cord blood (PCB). BioArchive Systems are currently in use at the major cord blood banks in Japan, China, Taiwan, Vietnam, Germany, Spain, Finland, U.K., Belgium and the U.S.
The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell units in liquid nitrogen at -196 degrees C that have been collected and processed in proprietary sterile plastic bag sets. The BioArchive System performs a precise controlled-rate freeze, tracks identification and archive location and performs robotic storage and retrieval of each unique tissue-typed PCB unit for use in life-saving transplantation. A specialized transfusion bag set is used to administer the stem cells to the patient. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE) which can reduce cell viability. PCB stem cells are used to reconstitute the hematopoietic and immune systems of patients who have undergone high-dose chemotherapy and radiation to combat diseases such as leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem cell disorders.
According to Philip Coelho, Chairman and CEO of the Company, "Recent research suggests that there are stem cells in a unit of cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver and bone cells. Since there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists may begin to focus on cord blood as a superior, non-controversial source for stem cells." The BioArchive System has additional potential applications involving archiving, storing, managing and retrieving of other kinds of biological specimens, including peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples.
Regulatory Status
The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to IND sites which have received FDA approvals for use with stem cell storage for transplant into unrelated patients. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for preservation of blood components and blood products and would require FDA 510(k) clearance for some additional claims.
Regulatory Status
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.
Contact: THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
jgodsey@thermogenesis.com
www.thermogenesis.com
Source: BusinessWire
BusinessWire
Monday September 25 6:05am
RANCHO CORDOVA, Calif.--(BW HealthWire)--Sept. 25, 2000-- THERMOGENESIS CORP. (Nasdaq NM: KOOL) announced today that it has received notice from the U.S. Patent Office of the issuance of a patent describing a disposable bag set configured to isolate a stem cell rich fraction of blood into a fixed volume during centrifugation. THERMOGENESIS` patent portfolio includes 15 issued and eight pending U.S. patents.
Dr. James Godsey, President and COO of THERMOGENESIS CORP., noted that this improved bag set could be integrated into the BioArchive System of devices and disposals for processing hematopoietic stem cells from placental/umbilical cord blood (PCB). BioArchive Systems are currently in use at the major cord blood banks in Japan, China, Taiwan, Vietnam, Germany, Spain, Finland, U.K., Belgium and the U.S.
The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It uses a computer-driven robotic system to archive up to 3,626 PCB stem cell units in liquid nitrogen at -196 degrees C that have been collected and processed in proprietary sterile plastic bag sets. The BioArchive System performs a precise controlled-rate freeze, tracks identification and archive location and performs robotic storage and retrieval of each unique tissue-typed PCB unit for use in life-saving transplantation. A specialized transfusion bag set is used to administer the stem cells to the patient. The BioArchive System can freeze, place and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE) which can reduce cell viability. PCB stem cells are used to reconstitute the hematopoietic and immune systems of patients who have undergone high-dose chemotherapy and radiation to combat diseases such as leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem cell disorders.
According to Philip Coelho, Chairman and CEO of the Company, "Recent research suggests that there are stem cells in a unit of cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver and bone cells. Since there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists may begin to focus on cord blood as a superior, non-controversial source for stem cells." The BioArchive System has additional potential applications involving archiving, storing, managing and retrieving of other kinds of biological specimens, including peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples.
Regulatory Status
The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to IND sites which have received FDA approvals for use with stem cell storage for transplant into unrelated patients. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for preservation of blood components and blood products and would require FDA 510(k) clearance for some additional claims.
Regulatory Status
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.
Contact: THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
jgodsey@thermogenesis.com
www.thermogenesis.com
Source: BusinessWire
Hi Biotech-Fans,
auch die Aktie der Cytogen hat wieder enormes Aufholpotential. Sie liegt momentan zw. 8-9 Euro und sollte wohl in den nächsten Wochen in Richtung 12-15 Eur marschieren.
Sie hat viele interessante Produkte in der Pipeline und zudem seit heute noch eine Zusammenarbeit mit Progenics Pharm. abgeschlossen.
Hier die Nachricht in englich:
Press Release
SOURCE: Progenics Pharmaceuticals, Inc.
Progenics and Cytogen Select Therapeutic Prostate Cancer Vaccine for Human Testing
LAKE TAHOE, Nev., Sept. 25 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) and Cytogen Corporation (Nasdaq: CYTO - news) announced a new vaccine candidate that the companies will develop for the treatment of prostate cancer. The vaccine is directed against prostate specific membrane antigen (PSMA), a unique protein found on the surface of prostate cancer cells, and is designed to stimulate a patient`s immune system to recognize and destroy the cancer cells. The preclinical findings were reported at the 7th Annual CaP CURE Scientific Retreat, a gathering of more than 350 of the world`s leading prostate cancer researchers. This in vivo immunotherapy program is being conducted under a joint venture between Progenics and Cytogen.
The new vaccine is a genetically-engineered, or recombinant, form of the PSMA protein that comprises a portion of the protein that resides on the surface of prostate cancer cells and is fully accessible to the immune system. It is believed that the recombinant PSMA protein can be produced at large scale in a form suitable for human clinical testing. A highly purified form of the recombinant PSMA protein will be combined with a potent immunological stimulant, or adjuvant, to form the final vaccine product. The findings were described in an oral presentation by William C. Olson, Ph.D., Senior Director of Research & Development at Progenics.
``Based on our recent scientific advances, we have successfully produced a vaccine candidate that faithfully mimics the PSMA structure expressed on prostate cancer cells,`` said Dr. Olson. ``We believe that such a vaccine has the potential to induce an immune response in patients that is capable of eliminating prostate cancer cells. We expect to begin Phase I clinical studies next year.``
In addition to the recombinant PSMA protein vaccine approach described above, Progenics and Cytogen are also pursuing in parallel a vaccine strategy that utilizes novel and proprietary viral vectors which are designed to deliver the PSMA gene to the immune system. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA. In addition to their two vaccine programs directed at stimulating a patient`s immune system against his own cancer, Progenics and Cytogen have a therapeutic antibody program that includes ``naked``, radiolabelled, and toxin-conjugated monoclonal antibodies directed specifically at PSMA. The companies anticipate that a viral vaccine candidate as well as antibody-based therapies could also be tested in the clinic next year.
The PSMA gene was first discovered by scientists at Memorial Sloan-Kettering Cancer Center in New York City. PSMA is a cell-surface protein abundantly expressed on prostate cancer cells and therefore is an attractive target for vaccine and antibody-based cancer immunotherapies. Further work demonstrated that PSMA is also present at high levels on newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. These observations suggest that if PSMA-targeted therapies exhibit anti-angiogenesis effects, they may be valuable in treating a broad range of cancers.
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of cancer, viral, and other life-threatening diseases. The Company`s most advanced product, GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. A second cancer vaccine, MGV, with broad application to a variety of cancers, is entering Phase II trials. GMK and MGV are being developed in collaboration with Bristol-Myers Squibb Company. The Company`s lead HIV product, PRO 542, has completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV co-receptors, and with American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company is also developing a novel small-molecule antioxidant, DHA, to treat stroke and other disorders.
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed to development of novel products for the diagnosis, imaging, staging and treatment of cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex®, a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. AxCell Biosciences has agreed to enter into a collaboration with the Institute for Systems Biology to elucidate aberrations in protein signaling pathways underlying the metastatic spread of prostate cancer.
This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. The words `anticipates,` `plans,` `expects` and similar expressions identify forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the companies` actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the companies` corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the companies` Annual Reports on Form 10-K for the fiscal year ended December 31, 1999 and other periodic filings with the Securities and Exchange Commission. In particular, there can be no assurance that the companies` PSMA programs will result in a commercial product. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.
Contact: Ronald J. Prentki, President of Progenics Pharmaceuticals, 914-789-2800, rprentki@progenics.com; or Richard W. Krawiec, Ph.D., Vice President Investor Relations and Corporate Communications of Cytogen Corporation, 609-750-8289; or Renee Connolly, Media, Noonan-Russo Communications, 212-696-4455 ext. 227, renee@noonanrusso.com, for Progenics Pharmaceuticals
SOURCE: Progenics Pharmaceuticals, Inc.
CYTOGEN CORP. SHARES DL -, 01
Berlin 871813 8,00 G +0,30 +3,90% 13.050,00 19:42/25.09.
Frankfurt 871813 9,00 B +1,00 +12,50% 5.535,00 19:38/25.09.
XETRA 871813 9,95 +0,00 +0,00% 995,00 13:52/14.09.
Stuttgart 871813 8,00 B +0,20 +2,56% - 12:28/25.09.
München 871813 7,75 -T -0,25 -3,12% - 09:12/25
Heute legte sie teils 12% zu.
Also auch hier sehe ich gutes Potential nach oben.
Weitere News werden folgen.
mein KZ: 15-20 Euro
Gruß Hajo
auch die Aktie der Cytogen hat wieder enormes Aufholpotential. Sie liegt momentan zw. 8-9 Euro und sollte wohl in den nächsten Wochen in Richtung 12-15 Eur marschieren.
Sie hat viele interessante Produkte in der Pipeline und zudem seit heute noch eine Zusammenarbeit mit Progenics Pharm. abgeschlossen.
Hier die Nachricht in englich:
Press Release
SOURCE: Progenics Pharmaceuticals, Inc.
Progenics and Cytogen Select Therapeutic Prostate Cancer Vaccine for Human Testing
LAKE TAHOE, Nev., Sept. 25 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) and Cytogen Corporation (Nasdaq: CYTO - news) announced a new vaccine candidate that the companies will develop for the treatment of prostate cancer. The vaccine is directed against prostate specific membrane antigen (PSMA), a unique protein found on the surface of prostate cancer cells, and is designed to stimulate a patient`s immune system to recognize and destroy the cancer cells. The preclinical findings were reported at the 7th Annual CaP CURE Scientific Retreat, a gathering of more than 350 of the world`s leading prostate cancer researchers. This in vivo immunotherapy program is being conducted under a joint venture between Progenics and Cytogen.
The new vaccine is a genetically-engineered, or recombinant, form of the PSMA protein that comprises a portion of the protein that resides on the surface of prostate cancer cells and is fully accessible to the immune system. It is believed that the recombinant PSMA protein can be produced at large scale in a form suitable for human clinical testing. A highly purified form of the recombinant PSMA protein will be combined with a potent immunological stimulant, or adjuvant, to form the final vaccine product. The findings were described in an oral presentation by William C. Olson, Ph.D., Senior Director of Research & Development at Progenics.
``Based on our recent scientific advances, we have successfully produced a vaccine candidate that faithfully mimics the PSMA structure expressed on prostate cancer cells,`` said Dr. Olson. ``We believe that such a vaccine has the potential to induce an immune response in patients that is capable of eliminating prostate cancer cells. We expect to begin Phase I clinical studies next year.``
In addition to the recombinant PSMA protein vaccine approach described above, Progenics and Cytogen are also pursuing in parallel a vaccine strategy that utilizes novel and proprietary viral vectors which are designed to deliver the PSMA gene to the immune system. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA. In addition to their two vaccine programs directed at stimulating a patient`s immune system against his own cancer, Progenics and Cytogen have a therapeutic antibody program that includes ``naked``, radiolabelled, and toxin-conjugated monoclonal antibodies directed specifically at PSMA. The companies anticipate that a viral vaccine candidate as well as antibody-based therapies could also be tested in the clinic next year.
The PSMA gene was first discovered by scientists at Memorial Sloan-Kettering Cancer Center in New York City. PSMA is a cell-surface protein abundantly expressed on prostate cancer cells and therefore is an attractive target for vaccine and antibody-based cancer immunotherapies. Further work demonstrated that PSMA is also present at high levels on newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. These observations suggest that if PSMA-targeted therapies exhibit anti-angiogenesis effects, they may be valuable in treating a broad range of cancers.
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of cancer, viral, and other life-threatening diseases. The Company`s most advanced product, GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. A second cancer vaccine, MGV, with broad application to a variety of cancers, is entering Phase II trials. GMK and MGV are being developed in collaboration with Bristol-Myers Squibb Company. The Company`s lead HIV product, PRO 542, has completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV co-receptors, and with American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company is also developing a novel small-molecule antioxidant, DHA, to treat stroke and other disorders.
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed to development of novel products for the diagnosis, imaging, staging and treatment of cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex®, a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. AxCell Biosciences has agreed to enter into a collaboration with the Institute for Systems Biology to elucidate aberrations in protein signaling pathways underlying the metastatic spread of prostate cancer.
This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. The words `anticipates,` `plans,` `expects` and similar expressions identify forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the companies` actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the companies` corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the companies` Annual Reports on Form 10-K for the fiscal year ended December 31, 1999 and other periodic filings with the Securities and Exchange Commission. In particular, there can be no assurance that the companies` PSMA programs will result in a commercial product. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.
Contact: Ronald J. Prentki, President of Progenics Pharmaceuticals, 914-789-2800, rprentki@progenics.com; or Richard W. Krawiec, Ph.D., Vice President Investor Relations and Corporate Communications of Cytogen Corporation, 609-750-8289; or Renee Connolly, Media, Noonan-Russo Communications, 212-696-4455 ext. 227, renee@noonanrusso.com, for Progenics Pharmaceuticals
SOURCE: Progenics Pharmaceuticals, Inc.
CYTOGEN CORP. SHARES DL -, 01
Berlin 871813 8,00 G +0,30 +3,90% 13.050,00 19:42/25.09.
Frankfurt 871813 9,00 B +1,00 +12,50% 5.535,00 19:38/25.09.
XETRA 871813 9,95 +0,00 +0,00% 995,00 13:52/14.09.
Stuttgart 871813 8,00 B +0,20 +2,56% - 12:28/25.09.
München 871813 7,75 -T -0,25 -3,12% - 09:12/25
Heute legte sie teils 12% zu.
Also auch hier sehe ich gutes Potential nach oben.
Weitere News werden folgen.
mein KZ: 15-20 Euro
Gruß Hajo
Cytogen`s AxCell Biosciences and Molecular Staging to Investigate Biochips To Accelerate Mapping of Human Proteome
PR Newswire
Monday October 2 7:01am
Ultra-sensitive Prototype Assay for Prostate Cancer Marker Also Reported
PRINCETON, N.J., Oct. 2 /PRNewswire/ -- AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO) and Molecular Staging, Inc., (MSI), Guilford, CT, initiated a scientific plan to investigate potential synergies between their technologies to map protein pathways more rapidly and efficiently. MSI`s Rolling Circle Amplification Technology (RCAT(TM)) is a proprietary, highly sensitive and efficient amplification method for detecting the presence of target molecules micro-arrayed on a biochip. By combining AxCell`s domain-ligand interaction technology with MSI`s protein arrays, the two companies believe that they may be able to increase the rate of protein interaction measurements by 10 fold more than AxCell`s current rate of approximately 10,000 interactions per day.
"By amplifying the signals used to detect protein interactions, we plan to measure many different targets simultaneously on a biochip," explained John D. Rodwell, Ph.D., AxCell`s acting President and Chief Technical Officer. "The purpose of our joint effort is to evaluate the use of RCAT(TM) technology with the same signaling molecules used in AxCell`s interaction measurements. Although our current proprietary process for measuring protein-to-protein interactions continues to function successfully at planned commercial scale, this combined technique could allow us to use less material and to operate more efficiently using readily available equipment. Potential benefits of combining these automatable technologies include, ultra-high throughput affinity mapping and application of chip-based target arrays to protein expression."
Ultra-sensitive PSA assay demonstrates promise
As part of a separate ongoing collaboration between Cytogen and MSI, the companies today also announced that they have achieved their first milestone - proof of principle for an ultra-sensitive serum assay for prostate specific antigen (PSA), a widely used marker for the screening and detection of prostate cancer. Results using a panel of five antibodies to PSA indicate that the new RCAT-based assay has a sensitivity of more than 100 fold greater than existing commercial blood tests. Cytogen believes that an ultra- sensitive assay might lead to earlier detection of recurrent prostate cancer. The next step is the selection of one antibody for commercial development. The companies are also in the process of applying RCAT technology to establish proof of principle for an ultra-sensitive assay for prostate specific membrane antigen (PSMA), which Cytogen believes may have greater prognostic value than the PSA test alone.
This week, Cytogen and Molecular Staging are scheduled to make separate presentations at the UBS Warburg Global Life Sciences Conference in New York City, where more scientific details of an ultra-sensitive PSA test will be discussed.
AxCell profile
AxCell Biosciences Corporation has begun a two-to-four year project to develop a comprehensive, proprietary database of human protein signaling pathways as a tool for identifying new drug targets. Aberrations in the interactions of proteins with one another are at the heart of the molecular basis for many diseases. Structural proteomics, or protein expression, measures the number and types of proteins present in normal and diseased cells. This approach is useful in defining the structure of proteins in a cell. Some of these proteins may be targets for drug discovery. However, the role of proteins in disease states remains to be defined. AxCell`s proteomics business is focused upon functional proteomics, the study of proteins` biological activities. An important function of proteins is the transmission of signals using intricate pathways populated by proteins which interact with one another. Elucidating the role proteins play in these signaling pathways allows a better understanding of their function in cellular behavior and permits identification of potentially novel drug targets. Protein-protein interactions form the core of the Company`s Inter-functional Proteomic Database(TM) (IFP). AxCell is offering the IFP Database to the pharmaceutical industry as a tool to accelerate the drug discovery process. AxCell Biosciences has agreed to enter into a collaboration with the Institute for Systems Biology to elucidate aberrations in protein signaling pathways underlying the metastatic spread of prostate cancer. For additional information on AxCell Biosciences, visit www.axcellbio.com.
Molecular Staging Profile
Molecular Staging Inc., is a privately held biotechnology company developing improved diagnostic tests for a variety of diseases and advanced tools for genetic analysis. MSI`s core technology, Rolling Circle Amplification Technology, is a highly sensitive and efficient nucleic acid amplification technique that can be used to better detect, diagnose, and stage disease. Its technologies enable the rapid identification of molecular abnormalities affecting genes, proteins, and small molecules. Information on MSI and its products is available from its web site at www.molecularstaging.com.
Cytogen profile
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
Source: Cytogen Corporation
Contact: Richard W. Krawiec, Ph.D., Vice President, Investor Relations, Corporate Communications of Cytogen Corporation, 609-750-8289
Source: PR Newswire
PR Newswire
Monday October 2 7:01am
Ultra-sensitive Prototype Assay for Prostate Cancer Marker Also Reported
PRINCETON, N.J., Oct. 2 /PRNewswire/ -- AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO) and Molecular Staging, Inc., (MSI), Guilford, CT, initiated a scientific plan to investigate potential synergies between their technologies to map protein pathways more rapidly and efficiently. MSI`s Rolling Circle Amplification Technology (RCAT(TM)) is a proprietary, highly sensitive and efficient amplification method for detecting the presence of target molecules micro-arrayed on a biochip. By combining AxCell`s domain-ligand interaction technology with MSI`s protein arrays, the two companies believe that they may be able to increase the rate of protein interaction measurements by 10 fold more than AxCell`s current rate of approximately 10,000 interactions per day.
"By amplifying the signals used to detect protein interactions, we plan to measure many different targets simultaneously on a biochip," explained John D. Rodwell, Ph.D., AxCell`s acting President and Chief Technical Officer. "The purpose of our joint effort is to evaluate the use of RCAT(TM) technology with the same signaling molecules used in AxCell`s interaction measurements. Although our current proprietary process for measuring protein-to-protein interactions continues to function successfully at planned commercial scale, this combined technique could allow us to use less material and to operate more efficiently using readily available equipment. Potential benefits of combining these automatable technologies include, ultra-high throughput affinity mapping and application of chip-based target arrays to protein expression."
Ultra-sensitive PSA assay demonstrates promise
As part of a separate ongoing collaboration between Cytogen and MSI, the companies today also announced that they have achieved their first milestone - proof of principle for an ultra-sensitive serum assay for prostate specific antigen (PSA), a widely used marker for the screening and detection of prostate cancer. Results using a panel of five antibodies to PSA indicate that the new RCAT-based assay has a sensitivity of more than 100 fold greater than existing commercial blood tests. Cytogen believes that an ultra- sensitive assay might lead to earlier detection of recurrent prostate cancer. The next step is the selection of one antibody for commercial development. The companies are also in the process of applying RCAT technology to establish proof of principle for an ultra-sensitive assay for prostate specific membrane antigen (PSMA), which Cytogen believes may have greater prognostic value than the PSA test alone.
This week, Cytogen and Molecular Staging are scheduled to make separate presentations at the UBS Warburg Global Life Sciences Conference in New York City, where more scientific details of an ultra-sensitive PSA test will be discussed.
AxCell profile
AxCell Biosciences Corporation has begun a two-to-four year project to develop a comprehensive, proprietary database of human protein signaling pathways as a tool for identifying new drug targets. Aberrations in the interactions of proteins with one another are at the heart of the molecular basis for many diseases. Structural proteomics, or protein expression, measures the number and types of proteins present in normal and diseased cells. This approach is useful in defining the structure of proteins in a cell. Some of these proteins may be targets for drug discovery. However, the role of proteins in disease states remains to be defined. AxCell`s proteomics business is focused upon functional proteomics, the study of proteins` biological activities. An important function of proteins is the transmission of signals using intricate pathways populated by proteins which interact with one another. Elucidating the role proteins play in these signaling pathways allows a better understanding of their function in cellular behavior and permits identification of potentially novel drug targets. Protein-protein interactions form the core of the Company`s Inter-functional Proteomic Database(TM) (IFP). AxCell is offering the IFP Database to the pharmaceutical industry as a tool to accelerate the drug discovery process. AxCell Biosciences has agreed to enter into a collaboration with the Institute for Systems Biology to elucidate aberrations in protein signaling pathways underlying the metastatic spread of prostate cancer. For additional information on AxCell Biosciences, visit www.axcellbio.com.
Molecular Staging Profile
Molecular Staging Inc., is a privately held biotechnology company developing improved diagnostic tests for a variety of diseases and advanced tools for genetic analysis. MSI`s core technology, Rolling Circle Amplification Technology, is a highly sensitive and efficient nucleic acid amplification technique that can be used to better detect, diagnose, and stage disease. Its technologies enable the rapid identification of molecular abnormalities affecting genes, proteins, and small molecules. Information on MSI and its products is available from its web site at www.molecularstaging.com.
Cytogen profile
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. For additional information visit www.cytogen.com.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
Source: Cytogen Corporation
Contact: Richard W. Krawiec, Ph.D., Vice President, Investor Relations, Corporate Communications of Cytogen Corporation, 609-750-8289
Source: PR Newswire
Frage mich nur, wieso keiner in Europa die Aktie kennt! Cytogen scheint sich ähnlich wie medarex zu entwickeln
Cytogen - News:
Cytogen Announces $70 Million Equity Financing Facility
PR Newswire
Tuesday October 10 7:02am
PRINCETON, N.J., Oct. 10 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) announced today that it has entered into an equity financing facility from Acqua Wellington North American Equities Fund, Ltd. ("Aqua Wellington") for up to $70 million. Over the next 20 months, Cytogen may, at its discretion, sell additional shares of its common stock to Acqua Wellington pursuant to this financing facility at a small discount to market to be determined before each sale. This financing facility is not subject to any minimum takedown requirements, nor did the Company pay any fees or other compensation in connection with this transaction. Recently, Cytogen also received $6 million in net proceeds from an equity placement of 902,601 shares of registered common stock with Acqua Wellington. Cytogen plans to use the proceeds of this transaction to accelerate its proteomic and drug development programs as well as for general corporate purposes.
"This financing facility will give Cytogen the ability to access capital as needed to accelerate development of our proteomics program and to continue our focus on strategies that will enhance shareholder value," said Lawrence R. Hoffman, Cytogen`s Vice President and Chief Financial Officer. "With increased financial resources, including the anticipated sale of tax benefits this year through the State of New Jersey, Cytogen will be in a stronger position to move its products through development, to acquire or to in-license additional products that complement our business objectives in proteomics and prostate cancer, and to pursue additional strategic partnerships."
Acqua Wellington Asset Management, LLC acts as the advisor to the Acqua Wellington Family of Funds, which is targeted at investment opportunities among mid-cap and small-cap publicly traded companies in domestic and global markets. Their primary focus is in the technology and life science sectors.
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in-vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to successfully complete the sale of its New Jersey tax benefits under the State of New Jersey`s tax loss sale program, to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
Source: Cytogen Corporation
Contact: Richard W. Krawiec, Ph.D., Vice President, Investor Relations, Corporate Communications of Cytogen, 609-750-8289
Source: PR Newswire
Cytogen Announces $70 Million Equity Financing Facility
PR Newswire
Tuesday October 10 7:02am
PRINCETON, N.J., Oct. 10 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) announced today that it has entered into an equity financing facility from Acqua Wellington North American Equities Fund, Ltd. ("Aqua Wellington") for up to $70 million. Over the next 20 months, Cytogen may, at its discretion, sell additional shares of its common stock to Acqua Wellington pursuant to this financing facility at a small discount to market to be determined before each sale. This financing facility is not subject to any minimum takedown requirements, nor did the Company pay any fees or other compensation in connection with this transaction. Recently, Cytogen also received $6 million in net proceeds from an equity placement of 902,601 shares of registered common stock with Acqua Wellington. Cytogen plans to use the proceeds of this transaction to accelerate its proteomic and drug development programs as well as for general corporate purposes.
"This financing facility will give Cytogen the ability to access capital as needed to accelerate development of our proteomics program and to continue our focus on strategies that will enhance shareholder value," said Lawrence R. Hoffman, Cytogen`s Vice President and Chief Financial Officer. "With increased financial resources, including the anticipated sale of tax benefits this year through the State of New Jersey, Cytogen will be in a stronger position to move its products through development, to acquire or to in-license additional products that complement our business objectives in proteomics and prostate cancer, and to pursue additional strategic partnerships."
Acqua Wellington Asset Management, LLC acts as the advisor to the Acqua Wellington Family of Funds, which is targeted at investment opportunities among mid-cap and small-cap publicly traded companies in domestic and global markets. Their primary focus is in the technology and life science sectors.
Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in-vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to successfully complete the sale of its New Jersey tax benefits under the State of New Jersey`s tax loss sale program, to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.
Source: Cytogen Corporation
Contact: Richard W. Krawiec, Ph.D., Vice President, Investor Relations, Corporate Communications of Cytogen, 609-750-8289
Source: PR Newswire
Schöner Sprung heute gegen Handelsschluß an der Nas. Mal nachrechnen 5,93 $ ergeben ca. 7,04 Eu. Schön! Endlich! Habe bei 7 Eu
gekauft. War schon kurz davor zu verkaufen.
Frage mich nur wie der Sprung heute zustande kam....? Ob da aufregende news bekannt geworden sind? Quartalszahlen gibts nächste
Woche, oder?
Weitere Frage: Wieso ist Medarex so pervers gestiegen und Cytogen nicht? Na ja, ich warte einfach noch ein, zwei Jahre. Im Prinzip
arbeiten die beiden mit den gleichen Mitteln.
20 sollten innerhalb der nächsten paar Monate wieder erreichbar sein.
by the way: WIESO KENNT KEINER IN DEUTSCHLAND DIESE AKTIE???
Dies kann nur eines für uns bedeuten: AKTIE BEKANNT MACHEN!
ragingbull.altavista.com hat ein gutes Forum zu diesem stock! Schaut mal vorbei!
go cyto, go!
gekauft. War schon kurz davor zu verkaufen.
Frage mich nur wie der Sprung heute zustande kam....? Ob da aufregende news bekannt geworden sind? Quartalszahlen gibts nächste
Woche, oder?
Weitere Frage: Wieso ist Medarex so pervers gestiegen und Cytogen nicht? Na ja, ich warte einfach noch ein, zwei Jahre. Im Prinzip
arbeiten die beiden mit den gleichen Mitteln.
20 sollten innerhalb der nächsten paar Monate wieder erreichbar sein.
by the way: WIESO KENNT KEINER IN DEUTSCHLAND DIESE AKTIE???
Dies kann nur eines für uns bedeuten: AKTIE BEKANNT MACHEN!
ragingbull.altavista.com hat ein gutes Forum zu diesem stock! Schaut mal vorbei!
go cyto, go!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 241 | ||
| 102 | ||
| 81 | ||
| 79 | ||
| 75 | ||
| 53 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 30 | ||
| 28 | ||
| 24 | ||
| 24 | ||
| 24 | ||
| 23 | ||
| 21 | ||
| 20 | ||
| 19 |
